Cabinet Medical Van Houte Cornejo Montero
- Address
- lock Available on a paid plan
Neoplasms Research
At Cabinet Medical Van Houte Cornejo Montero in Yvoir, clinical trials in oncology focus on major cancers such as non-small cell lung cancer and metastatic renal cell carcinoma. These studies are designed to evaluate whether new treatment strategies can improve survival and disease control compared with current standard care.
- Testing whether immunotherapy can help prevent recurrence after surgery for early-stage lung cancer
- Comparing treatment approaches for metastatic renal cell carcinoma to improve survival outcomes
This research reflects a strong interest in advancing cancer care through better use of immune-based therapies and other targeted treatment options.
Respiratory Tract Diseases Research
The site's pneumology program includes trials in respiratory medicine for conditions such as progressive fibrosing interstitial lung diseases. The aim is to assess whether new therapies can slow lung function decline and improve outcomes for people with chronic, worsening lung disease.
- Evaluating a new treatment for progressive fibrosing interstitial lung diseases
- Measuring changes in lung function to understand treatment benefit
This work highlights the clinic's role in studying therapies that may help preserve breathing capacity and quality of life in patients with serious interstitial lung disease.
Hematologic Malignancies and Other Research
In addition to solid tumors and lung disease, the site is involved in studies of acute lymphoblastic leukemia in older adults. These trials are focused on finding safer and more effective treatment options for patients who may need gentler approaches because of age or overall health.
- Assessing a treatment strategy for newly diagnosed Philadelphia-negative B-cell precursor acute lymphoblastic leukemia
- Comparing event-free survival and overall survival with alternative treatment approaches
The research portfolio also includes work that is not limited to a single disease area, showing a broader effort to refine cancer therapy and support better treatment selection across different patient groups.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 therapeutic areas and 15 of 24 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 307 other sites in Belgium
Therapeutic Area Benchmark — Belgium
Select a therapeutic area to compare against other sites in Belgium.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Belgium
Market Share
Country: Belgium
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Cabinet Medical Van Houte Cornejo Montero
lock Showing 1 of 6 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A randomized, double-blind, multicenter phase III study to evaluate the long-term efficacy and safety of ABX464 25 mg or 50 mg once daily as a maintenance therapy in subjects with moderately to severely active ulcerative colitis | Abivax | Phase III | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 24 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Obefazimod | 2 | Unknown | — | — |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.